Published online Dec 15, 2014. doi: 10.4239/wjd.v5.i6.924
Revised: September 29, 2014
Accepted: November 7, 2014
Published online: December 15, 2014
The association between adipokines and inflammatory periodontal diseases has been studied over the last two decades. This review was intended to explore the observation that periodontal therapy may lead to an improvement of adipokines in diabetic patients. In summary, substantial evidence suggests that diabetes is associated with increased prevalence, extent and severity of periodontitis. Numerous mechanisms have been elucidated to explain the impact of diabetes on the periodontium. However, current knowledge concerning the role of major adipokines indicates only some of their associations with the pathogenesis of periodontitis in type 2 diabetes. Conversely, treatment of periodontal disease and reduction of oral inflammation may have positive effects on the diabetic condition, although evidence for this remains somewhat equivocal.
Core tip: Several adipokines could serves as the monitoring molecules that reflect overall and oral disease conditions include periodontitis. Because they are rapidly change upon the change in body and oral conditions. The treatment response and disease activity progression may also predicted using these kinds of molecules. Moreover, the method to collect and analyse adipokines is relatively simple because they can be detected in gingival crevicular fluid and analysed using general enzyme-linked immunosorbent assay technology. Collectively, clinicians include medical doctors and periodontists should take the concern regarding adipokines into their routine periodontal treatment plan and management.